A skin booster is an injection that places material into the skin to address hydration and elasticity. They share a name, but Rejuran, Juvelook, Profhilo, and Re2O contain different materials. Choosing starts not from a popularity ranking, but from asking whether the present concern is hydration, texture, or elasticity, and matching that to the material.
3-line summary
A skin booster is not one material, but a group of injections with different materials such as PN, PDLLA, HA, and hADM.
In consultation they are divided as Rejuran for texture, Juvelook for hydration and later elasticity, Profhilo for hydration, and Re2O as a skin-scaffold material.
Session count and interval differ by product, and pregnancy, infection, allergy, and medications should be disclosed before treatment.
A skin booster is a group of injections with different materials
An overview compiled by Korean researchers also treats skin boosters as injections covering several biomaterials. If filler fills a hollow in the contour, a skin booster targets hydration, texture, and elasticity of the skin itself. Glow injection is a catch-all name for shallow hyaluronic acid injections, so product names vary.
The first question in consultation is not “Should I get a skin booster?” but “Which material should be placed?” Product-level detail continues in the complete skin booster guide.
Dividing the four products by material
The four products often compared are not items to rank. They are divided by what is placed. The schedule column is an example used in each study.
| Product | Material injected | Changes discussed in consultation | Schedule used in studies |
|---|---|---|---|
| Rejuran | Polynucleotide (PN) | Gradual change in texture and wrinkles | Observed up to three months in an eye-area comparison study |
| Juvelook | Poly-D,L-lactic acid (PDLLA) and non-cross-linked hyaluronic acid | Hydration and later elasticity | Two or three sessions at 4-week intervals in a preliminary study |
| Profhilo | High- and low-molecular-weight hyaluronic acid heat-stabilized | Hydration and skin elasticity | Two sessions one month apart, four-month observation, in an open-label study |
| Re2O | Human dermal scaffold with cells removed (hADM) | Skin measures such as density and elasticity | Observed up to five months in a comparison study |
※ The schedule in the table is the point at which the study finished measuring. Individual plans vary with site and formulation.
The material in Rejuran is PN. A literature review of PN injections gathered studies that observed changes in wrinkles, texture, and elasticity, and mild reactions at the injection site generally did not last long. Among the review authors is someone who served in an education role for a related product company. The eye-area comparison study can be read further in the Rejuran Healer guide.
Juvelook contains PDLLA together with non-cross-linked hyaluronic acid. In a preliminary study the count of reported serious adverse events was tallied as 0, and the manufacturer funded the research. For formulation detail, see the Juvelook guide.
Profhilo is a product that heat-stabilizes two hyaluronic acids. In an open-label study of women only, 23% of participants had a temporary reaction at the injection site, and the manufacturer funded the research. Ingredient comparison continues in the Profhilo guide.
Re2O does not place living cells. It places a scaffold material left after cells are removed from donated skin. In a comparative study in people the count of reported serious adverse events was tallied as 0, and one author advised on development of the product. The material is described in the Re2O skin booster guide.
Questions to ask in consultation
Writing down the material, session count, and same-day reactions—rather than the product name alone—makes it easier to check the explanation. The questions below can be asked as they are in consultation.
- □ What is the exact name and injected material of the product suggested today?
- □ Which of my concerns—hydration, texture, or elasticity—does that material correspond to?
- □ How many sessions, and how many days apart, is the plan?
- □ How many days do you expect the redness, swelling, or bruising on the day to last?
- □ How are blood-thinning medicines, immunosuppressants, and recent facial injections reflected in the schedule?
Treatment day and recovery
All four products are injections. After numbing cream is applied the material is placed, and the injection sites may be red or swollen on the day. Estimates are given in consultation according to session count and site.
| Time point | Common reactions |
|---|---|
| Immediately after treatment | Redness, swelling, and small bumps at the injection sites |
| The following days | Bruising appearing or settling |
| Recovery period | Makeup, saunas, and strong sunlight follow the product instructions |
Shared precautions can be confirmed in the treatment safety information.
Frequently asked questions
Q1. Are skin boosters painful?
There is injection pain, and redness, swelling, and bruising on the day are common. Numbing cream is often applied first.
Q2. How many sessions?
The Juvelook preliminary study used two or three sessions at 4-week intervals; the Profhilo open-label study used two sessions one month apart. Session counts for Rejuran and Re2O vary with formulation and site, so compare the table schedule with the actual plan in consultation.
Q3. How long do the effects last?
The periods written in the table are the points at which the studies finished measuring. Later status was not measured in those sources. How it feels varies with skin condition and daily habits.
Q4. Can several types be received together?
If the materials differ, a plan that separates sequence and interval can be considered. Whether to stack several injections on the same day is decided by looking at recovery and injection sites. Please also disclose recent facial injections.
Q5. Who should not receive it?
The schedule is postponed if there is pregnancy or breastfeeding, inflammation at the treatment site, or an ingredient allergy. Blood-thinning medicines and immunosuppressants should not be stopped on one’s own; they are reflected in the schedule after discussion with the prescribing clinician.
Results, duration, and suitability vary with individual skin condition, age, and lifestyle, and the same outcome cannot be guaranteed.
Procedures may cause temporary redness or swelling, and contraindications may apply, so please confirm these during your consultation.
This article is general information and does not replace individual medical care. Please confirm diagnosis and treatment suited to your condition during a consultation.
Sources
- PMID 39544509 — Overview that a skin booster is an injection of various biomaterials; classifies Juvelook as a PDLLA product. Verified scope: Europe PMC full text. Design limitations: a review, not a clinical trial measuring the effect of individual products. No author conflict-of-interest declaration.
- PMID 39645667 — Literature review of PN injections. Verified scope: abstract. Design limitations: included studies of low or moderate quality; lack of consensus on optimal use. Among the authors is someone who served in education and advisory roles for a related product company.
- PMID 31680395 — Left-right comparison around the eyes of a purified PN filler (Rejuran) and another material. Verified scope: abstract. Design limitations: limited to the eye area, three-month observation, small sample.
- PMID 37969055 — Juvelook (PDLLA+non-cross-linked HA) preliminary study, two or three sessions at 4-week intervals, reported serious adverse events 0. Verified scope: abstract and methods section (product name and composition). Design limitations: preliminary study, before-after comparison without a control group. Manufacturer (VAIM) research funding.
- PMID 27713647 — Profhilo (IBSA) open-label study. Women only, two sessions one month apart, four-month observation, temporary injection-site reactions 23%. Verified scope: abstract + Europe PMC full text (product name and funding). Design limitations: open-label, single center, no control group. Manufacturer research funding.
- PMID 32685528 — Profhilo post-marketing safety report. Heat process (stabilized without chemical reagents); spontaneously reported adverse events were mainly swelling, redness, and bruising at the injection site. Verified scope: abstract. Design limitations: spontaneous reporting, so mild cases may be missed. Authors include manufacturer employees.
- PMID 41828422 — Injectable hADM (related to Re2O) left-right comparison, five-month observation, reported serious adverse events 0. Verified scope: abstract. Design limitations: adults with cheek roughness; observation stopped at five months. One author advised on development of the product.
Related reading
Sources
Discuss options for your current needs
We review your current health and prior procedures before explaining appropriate options and their limits.
